Citizens Maintains Market Outperform on Zymeworks, Raises Price Target to $39

Benzinga · 1d ago
Citizens analyst Reni Benjamin maintains Zymeworks (NASDAQ:ZYME) with a Market Outperform and raises the price target from $32 to $39.